This is an early scientific progress update that does not alter the clinical or regulatory timeline. No catalyst for stock movement. Monitor for next clinical milestone or partnership announcement for EVX-V1, which is still in preclinical development and years from potential commercialization.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 13 $3.02entry
- T+1 · 4mo ago +0.33%α −0.02% · $3.03
- T+5 · 4mo ago +1.82%α +2.61% · $3.08
- T+20 · 3mo ago +0.99%α −2.19% · $3.05
- T+60 · 6w ago +4.64%α +0.64% · $3.16
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evaxion announced new preclinical data for its CMV vaccine program EVX-V1, presented at an industry conference. The data shows AI-discovered T-cell epitopes improved control of acute infection, latency, and reactivation in mice, supporting the multi-component vaccine concept. This is an early-stage scientific update with no clinical data or regulatory milestone, and the stock has historically declined on similar neutral-content filings.
Key Facts
- New preclinical data for EVX-V1 presented at International Herpesvirus Workshop 2026 in Montreal
- Data show AI-discovered novel T-cell epitopes improved control of acute infection, latency, and reactivation in CMV-infected mice
- EVX-V1 combines novel AI-discovered B-cell and T-cell antigens with AI-optimized versions of established CMV antigens
- No licensed CMV vaccine currently exists; CMV treatment market valued at $474.6M in 2023, CAGR 6.6%
- Evaxion is a clinical-stage TechBio company with $26M market cap; no financial data or guidance provided in this filing
Financial Impact
No financial figures reported; preclinical data update with no revenue or cost implications
Risk Factors
- Preclinical data may not translate to human clinical results
- EVX-V1 remains in early development; no IND or Phase 1 start announced
- Evaxion's need for additional capital could lead to dilution before EVX-V1 reaches clinic
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-004586 |
| Document: f6k_071026.htm | 0001171843-26-004586 |
| Document: 0001171843-26-004586-index-headers.html | 0001171843-26-004586 |
| Document: 0001171843-26-004586-index.html | 0001171843-26-004586 |
| Document: 0001171843-26-004586.txt | 0001171843-26-004586 |
Track record
50 reports on EVAX
7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers